REVO Oncology has built first of its kind AI/ML platform that analyzes the patient’s DNA and determines which therapies are most likely to work, extending lives and reducing toxic side effects of over treatment.
Industry: Biotechnology
Market Size: $14B TAM, $8B SAM, $4B SOM
Capital Seeking: Raising $2M SAFE, $10M valuation cap
Use of Funds: Commercialization, customer site implementation, first hires
Management Team
Estevan Kiernan
CEO & Founder
15+yrs oncology diagnostics sales, business dev at Thermo Fisher, Abbott and Illumina
Dr. Han-Yu Chuang PhD
CTO
15+yrs diagnostic executive, led startup and leading biotech org product development and bioinformatics
Contracts: Commercialization from national lab & paid pilot
Contracts in flight: National Cancer Institute, Largest gene technology co, multiple health systems
Grant pre-approved by tech provider
Novel IP published in NATURE
Traction
Problem
Chemotherapy is the most common therapy used in cancer despite uncertain benefit, leading to toxicity, treatment delays and costs. As more therapies become available, smarter diagnostics are urgently needed to simplify decision making and customize care.
Solution
We’re commercializing our AI/ML platform that predicts the best combination of cancer therapies patient will best respond to for their cancer. Our core test can be used standalone or as a bolt-on to on-market tests, delivering actionable results at a single decision point without adding lab complexity or cost.
Business Model
Unlike other models that require insurance reimbursement, our first asset will be licensed to hospital labs, service providers and pharma partners on a annual/per patient basis. We will also pursue insurance reimbursement as an additional source of revenue and expanded business model.
Market
Targeting $14B oncology diagnostics market, starting with lung cancer (235k U.S. cases/yr) and expanding into breast and colorectal cancers. Our novel chemoresponse test can be used as a wedge to access multiple markets with differentiated offerings.
Competition
REVO Oncology is first to market and does not have any direct competition. This enables multiple partnership opportunities including Guardant, Foundation Medicine, Quest, Lab Corp, Tempus, Illumina and Thermo Fisher. Exact Sciences has a widely adopted chemoresponse adjacent test($700M ARR) for a breast cancer subpopulation, but it lacks chemo class specificity.